1Mês·

Announcement of the Next Company Presentation

Hello, everyone,

Given that I’d like to take a slightly more defensive stance due to the upcoming events,

and since I don’t want to increase my semiconductor holdings for now, I’m still looking for a defensive stock for my core portfolio.

Based on some positive analyst comments, the first stock will be

Eli Lilly $LLY (+3,15%) .

Attached are the quarterly results and links to the analyst comments. (No advertising)

I’ll present the company overview for you in a second post.

Feel free to share your thoughts in the comments.

Dominance in the Diabetes Market

Eli Lilly’s leadership in diabetes and obesity treatments, led by Mounjaro and Zepbound, is driving impressive revenue growth and market share gains

Pipeline Potential

An examination of Eli Lilly’s diverse pipeline, including Orforglipron for obesity and advances in gene editing, which position the company for sustainable growth

Eli Lilly and Company: Earnings Call Q2/2026 - Roundup

Revenue in the second quarter reached $22.97 billion, a 48% increase year-over-year, and exceeded estimates by $2.41 billion; Mounjaro and Zepbound together contributed $14.9 billion to revenue.
Earnings per share (EPS) of $8.38 missed the forecast of $8.84 due to research and development (R&D) expenses of $3.03 per share; The stock rose 2.26% to $1,140.86 in premarket trading.
The full-year 2026 guidance was raised: Revenue is now expected to be between $85 billion and $87 billion, adjusted earnings per share (non-GAAP EPS) between $35.50 and $36.50, and the performance margin between 49% and 50.5%.
The Medicare GLP-1 Bridge Program was launched on July 1, providing 20 million Americans with access to obesity medications at a copay of $50 per month.
The filing for Retatrutide in the U.S. is scheduled for the first quarter of 2027; the number of Foundayo prescribers rose from 8,000 to 36,000, and this drug is now used in one out of every four new treatment starts.

Analysten-Upgrade und Markterfolge beflügeln Eli Lilly Aktie

Investing.com
1 hour ago

Eli Lilly präsentiert auf EASD-Konferenz neue Daten zu kardiometabolischen Medikamenten

Investing.com
2 hours ago

EASD 2026: Eli Lilly präsentiert neue Studiendaten zu Diabetes- und Adipositas-Medikamenten

Investing.com
2 hours ago

ANALYSE-FLASH: Berenberg hebt Eli Lilly auf ’Buy’ - Ziel 1400 Dollar

dpa-AFX
3 hours ago

Neues Analysten-Update zu Eli Lilly And Co

Pro

Investing.com
7 hours ago

11 Comentários

Alois_Loves_Stocks@Alois_Loves_Stocks

1Mês

I added these to my portfolio a few days ago for similar reasons 😁✌🏼

•

Steppenwolf66@Steppenwolf66

1Mês

I decided to treat myself to 13 shares of BridgeBio at 61.88

•

Raketentoni@Raketentoni

1Mês

Today, I’m sharing my personal opinion—not Mr. Prompt’s 😬
I think the biggest issue with Eli is concentration: Mounjaro and Zepbound already accounted for about 65% of total revenue in the first half of 2026.

Personally, I think that’s enormous. On top of that, there’s price pressure, competition from Novo Nordisk and possibly Amgen in the future, regulatory risks, and high production capex.

On the other hand, Lilly’s valuation is now less absurd than it was two years ago, but it’s still expensive: most recently around 37× earnings or 27× forward earnings.
For this level of growth, that’s not completely crazy, but it’s certainly no bargain either.

I have it on my watchlist, and it’ll be pitted against Ferrovial and Intuit tonight.

•

Tenbagger-Capital@Tenbagger-Capital

1Mês

@Raketentoni I'm looking forward to it; the presentation is coming up soon. I hope there will be a comment on it, too.

•

Danone1986@Danone1986

4Semana

In the long term, many more great products will hit the market besides the weight-loss peptide. Lilly could have made a nice profit at under 600—unfortunately, they weren't greedy enough 😑

•

Ricola@Roccola601

1Mês

Which "upcoming events" worry you the most?

••

Tenbagger-Capital@Tenbagger-Capital

1Mês

@Roccola601 I'm not worried. I think the rate hike will be partially priced in. And as for the midterms, we'll just have to wait and see. High oil prices and bond yields are actually more of a concern.

•

Ricola@Roccola601

1Mês

@Tenbagger-Capital I agree with you, and I had already thought that's what it was referring to. Yes, the rate hike is largely priced in (it’ll be interesting to see how the market reacts if—for reasons that are hard to explain—it doesn’t happen)—generally speaking, I have to say that I’d actually like the negative market environment to last a little longer right now, because in some cases it’s really bringing some interesting opportunities again...

••

Tenbagger-Capital@Tenbagger-Capital

1Mês

@Roccola601 The narrative surrounding AI has also led to another nice correction. These are actually good entry points.

•

Ricola@Roccola601

1Mês

@Tenbagger-Capital especially since, when you look at it objectively, it’s really just a narrative at first—one that isn’t reflected in the financial statements—and those are actually always the best opportunities. Nevertheless, I certainly understand many of the concerns and, as I’ve done elsewhere, will work on expanding “counterbalances” to AI in the portfolio 🙏🏼

••

Tenbagger-Capital@Tenbagger-Capital

1Mês

@Roccola601 Perhaps we'll also expand into energy. That will remain an issue. The same goes for robotics.

•